ArticleJournal of robotic surgery2025
Comparative analysis of Robotic-Assisted, Laparoscopic, and open radical nephrectomy: Utilization, Costs, and clinical outcomes.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimally invasive approaches, including laparoscopic (LARN) and robotic-assisted radical nephrectomy (RARN), have gained adoption over open surgery (ORN) for renal cancer, despite RARN’s higher costs. This contemporary study evaluates trends in RARN, LARN, and ORN use and compares their hospital costs, clinical complications, and mortality rates.
methodsPatients undergoing radical nephrectomy (2016–2019) were identified from the National Inpatient Sample (NIS). Procedures were classified as RARN, LARN, or ORN using ICD-10 and Procedure Coding System codes. Patient demographics and comorbidities, hospital characteristics, length of stay (LOS), clinical complications, and hospital costs were analyzed. Trends in utilization were assessed, and regression models adjusted for patient and hospital factors examined associations between surgical approach and inpatient perioperative outcomes, including complications, mortality, LOS, and hospital costs.
resultsAmong 154,115 patients, 39.5% underwent LARN, 25.7% RARN, and 34.8% ORN. Annual RARN utilization increased (21.8% to 29.6%), while LARN declined (44.8% to 35.2%). RARN was more common in older and comorbid patients. Median costs were lowest for LARN ($13,950) compared to RARN ($16,771) and ORN ($17,821). Both RARN and LARN had lower inpatient perioperative complications, blood transfusion rates, and mortality than ORN. RARN and LARN were associated with reduced LOS and costs relative to ORN. While RARN was 15% more expensive than LARN, it had 5% shorter LOS. A limitation was the absence of tumor characteristic data.
conclusionsRARN and LARN are increasingly used and both demonstrated better inpatient perioperative outcomes than ORN. However, RARN offers no clear clinical advantage over LARN and remains more costly than LARN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.